Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

European Journal of Immunology

Volumn 32, Issue 11, 2002, Pages 3267-3275

  Golgher, Denise ^a   Jones, Emma ^b   Powrie, Fiona ^c   Elliott, Tim ^a   Gallimore, Awen ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CT26; Regulatory T cell; Shared antigen; Tumor immunity

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; TUMOR ANTIGEN; TUMOR REJECTION ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; CANCER CLASSIFICATION; COLORECTAL TUMOR; CONTROLLED STUDY; CROSS REACTION; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TARGET CELL; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; CROSS REACTIONS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0036858838     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1     Document Type: Review

References (45)

1. Boon, T. and Old, L. J., Cancer Tumor antigens. Curr. Opin. Immunol. 1997. 9: 681-683.
2. Brandle, D., Bilsborough, J., Rulicke, T., Uyttenhove, C., Boon, T. and Van den Eynde, B. J., The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 1998. 28: 4010-4019.
3. Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E. and Rosenberg, S. A., A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 1996. 183: 1185-1192.
4. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M. and Eisenbach, L., CTL induction by a tumor-associated antigen octapepticle derived from a murine lung carcinoma. Nature 1994. 369: 67-71.
5. Monach, R A., Meredith, S. C., Siegel, C. T. and Schreiber, H, A unique tumor antigen produced by a single amino acid substitution. Immunity 1995. 2: 45-59.
6. Gilboa, E., The makings of a tumor rejection antigen. Immunity 1999. 11: 263-270.
7. Singh, S., Ross, S. R., Acena, M., Rowley, D. A. and Schreiber, H., Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 1992. 175: 139-146.
8. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H. and Zinkernagel, R. M., Roles of tumor localization, second signals and cross-priming in cytotoxic T cell induction. Nature 2001. 411: 1058-1064.
9. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. and Levitsky, H., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998. 95: 1178-1183.
10. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity and transplantation tolerance. Immunol. Rev. 2001. 182: 18-32.
11. Maloy, K. J. and Powrie, F., Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001. 2: 816-822.
12. Shevach, E. M., Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 2000. 18: 423-449.
13. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 5211-5218.
14. + immunoregulatory cells. J. Immunol. 2001. 167: 1137-1140.
15. ++ regulatory cells that control intestinal inflammation. J. Exp. Med. 2000. 192: 295-302.
16. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000. 12: 431-440.
17. + T cells that prevent diabetes onset in nonobese diabetic mice. J. Immunol. 2000. 164: 240-247.
18. Hara, M., Kingsley, C. I., Niimi, M., Read, S., Turvey, S. E., Bushell, A. R., Morris, P. J., Powrie, F. and Wood, K. J., IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 2001. 166: 3789-3796.
19. + T cells with regulatory properties from human blood. J. Exp. Med. 2001. 193: 1303-1310.
20. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001. 193: 1285-1294.
21. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 2001. 193: 1295-1302.
22. + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 2001. 31: 1247-1254.
23. + regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 2001. 194: 629-644.
24. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999. 59: 3128-3133.
25. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823-832.
26. Jones, E., Dahm-Vicker, M., Simon, A.K., Green, A., Powrie, F., Cerundolo, V. and Gallimore, A., Depletion of regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity 2002. 2: 1-11.
27. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R. C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 1993. 90: 3539-3543.
28. Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M. and Jaffee, E. M., The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 1996. 93: 9730-9735.
29. + T cell adoptive immunotherapy. Immunity 2000. 13: 265-276.
30. Golgher, D., Korangy, F., Gao, B., Gorski, K., Jaffee, E., Edidin, M., Pardoll, D. M. and Elliott, T., An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. J. Immunol. 2001. 167: 147-155.
31. Casares, N., Lasarte, J. J., de Cerio, A. L., Sarobe, P., Ruiz, M., Melero, I., Prieto, J. and Borras-Cuesta, F., Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol. 2001. 31: 1780-1789.
32. Adris, S., Chuluyan, E., Bravo, A., Berenstein, M., Klein, S., Jasnis, M., Carbone, C., Chernajovsky, Y. and Podhajcer, O. L., Mice vaccination with interleukin-12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res. 2000. 60: 6696-6703.
33. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S. and Zitvogel, L., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001. 7: 297-303.
34. Prehn, R. T and Main, M. J., Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 1957. 18: 769-778.
35. Lowenthal, J. W., Corthesy, P., Tougne, C., Lees, R., MacDonald, H. R. and Nabholz, M., High and low affinity IL-2 receptors: analysis by IL-2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 1985. 135: 3988-3994.
36. Qin, S., Cobbold, S., Tighe, H., Benjamin, R. and Waldmann, H., CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur. J. Immunol. 1987. 17: 1159-1165.
37. Ceredig, R., Lowenthal, J. W., Nabholz, M. and MacDonald, H. R., Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature 1985. 314: 98-100.
38. Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D. and Waldmann, H., Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 1984. 312: 548-551.
39. Corbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C. and Schabel, J., Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975. 35: 2434-2439.
40. Murphy, G. P. and Hrushesky, W. J., A murine renal cell carcinoma. J. Natl. Cancer Inst. 1973. 50: 1013-1025.
41. Tutt, A. L., French, R. R., Illidge, T. M., Honeychurch, J., McBride, H. M., Penfold, C. A., Fearon, D. T., Parkhouse, R. M., Klaus, G. G. and Glennie, M. J., Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 1998. 161: 3176-3185.
42. Mackett, M., Yilma, T., Rose, J. K. and Moss, B., Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 1985. 227: 433-435.
43. Lehmann-Grube, F., Assmann, U., Loliger, C., Moskophidis, D. and Lohler, J., Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice. J. Immunol. 1985. 134: 608-615.
44. Townsend, A., Bastin, J., Gould, K., Brownlee, G., Andrew, M., Coupar, B., Boyle, D., Chan, S. and Smith, G., Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 1988. 168: 1211-1224.
45. Salio, M., Cerundolo, V. and Lanzavecchia, A., Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells. Eur. J. Immunol. 2000. 30: 705-708.